TITLE

Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report

AUTHOR(S)
YUE FENG WANG; XIANHONG XIANG; XIAOJUAN PEI; SHUHUA LI; CUILAN TANG; LIANTANG WANG; ZUN-FU KE
PUB. DATE
September 2014
SOURCE
Oncology Letters;2014, Vol. 8 Issue 3, p1039
SOURCE TYPE
Academic Journal
DOC. TYPE
Case Study
ABSTRACT
Lung cancer is the leading cause of mortality among malignant diseases in humans worldwide. During the last decade, molecular targeted therapies for non-small cell lung cancer using first-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), including gefitinib, have been shown to be a promising approach for patients harboring activating mutations in EGFR. The current study reports a 77-year-old patient diagnosed with adenocarcinoma harboring L858R and T790M point mutations in the EGFR gene. The patient was treated with gefitinib as the second-line therapy, but no clinical benefit was observed. As the majority of patients with lung cancer receiving EGFR-TKI therapy acquire resistance, repeated biopsies and detection of the EGFR mutation state are beneficial for selecting appropriate treatments.
ACCESSION #
110397858

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics